Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 8/20 | 0.37 |
| ▸ | CA2 | P00918 | 8/20 | 0.37 |
| ▸ | MMP1 | P03956 | 8/20 | 0.37 |
| ▸ | MMP2 | P08253 | 8/20 | 0.37 |
| ▸ | MMP9 | P14780 | 8/20 | 0.37 |
| ▸ | MMP8 | P22894 | 8/20 | 0.37 |
| ▸ | MMP13 | P45452 | 8/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399965 | 0.98 | APOBEC3A (0.42) | APOBEC3AAPOBEC3GCA1CA2MMP1 | |
| SCHEMBL6395821 | 0.90 | CA2 (0.37) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL6396673 | 0.89 | CA2 (0.38) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL547720 | 0.87 | CA2 (0.38) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL5525260 | 0.80 | KDM4E (0.49) | CA1CA2MMP1MMP2MMP9 | |
| Biphenyl SCHEMBL1816739 | 0.80 | PTPN1 (0.47) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL6396639 | 0.79 | KDM4E (0.47) | CA1CA2MMP1MMP2MMP9 | |
| Tetramethylammonium Ion SCHEMBL548456 | 0.78 | CA2 (0.46) | CA1CA2MMP1MMP2MMP9 | |
| Iodobenzene SCHEMBL5315922 | 0.78 | CA2 (0.39) | CA1CA2MMP1MMP2MMP9 | |
| Benzenethiol SCHEMBL29745974 | 0.78 | CA2 (0.39) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6914092-B1 | Antistatic agent | BAYER AKTIENGESELLSCHAFT (DE) | 2005-07-05 | — | — | US | claimed |
| US-7169333-B2 | Antistatic agent | BAYER AKTIENGESELLSCHAFT (DE) | 2007-01-30 | — | — | US | disclosed |
| US-6914092-B1 | Antistatic agent | BAYER AKTIENGESELLSCHAFT (DE) | 2005-07-05 | — | — | US | disclosed |
| US-6914053-B2 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. (US) | 2005-07-05 | — | — | US | disclosed |
| US-20040121978-A1 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20030139503-A1 | Antistatic agent | COVESTRO DEUTSCHLAND AG (DE) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121978-A1 | Adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | APOBEC3A 207/4885APOBEC3G 309/4885CA1 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.